BOULDER, CO / ACCESSWIRE / January 31, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral plus nasal care, and wound care, today announced that it has entered into a distribution agreement along with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of Primocyn TM Skin Solution products in South Korea.
Daewoong Pharmaceutical is one of the largest pharmaceutical companies in South Korea, generating over $1 billion within revenues annually. Pursuant to the submission agreement, Daewoong Pharmaceutical will have the exclusive right in order to market, sell and distribute Primocyn Skin Solution items, containing Sonoma’s Microcyn technologies, in Southern Korea.
“We believe Primocyn Skin Answer, manufactured by Sonoma Pharmaceuticals, will provide healing and relief to our customers, and will complement our existing line associated with skin care plus healthcare products. We are pleased to be partnering with Sonoma as the distributor for these products in South Korea, ” said Chris Baik, Business Development and Pharmacist, for Daewoong Pharmaceutical.
“Daewoong Pharmaceutical is a leader in the pharmaceutical industry with significant knowledge of the healthcare and skin care markets in South Korea. Our Microcyn-powered Primocyn products have been sold within South Korea for years, and we look forward to this new partnership along with Daewoong Pharmaceutic to open up brand new sales channels and increase sales associated with Primocyn in South Korea, ” stated Amy Trombly, CEO of Sonoma Pharmaceuticals.
About Daewoong Pharmaceutical Co., Limited.
Since its establishment in 1945, Daewoong Pharmaceutical has grown to become one of the largest pharmaceutical companies within South Korea. With its strong plus competent in-house R& D and cGMP qualified manufacturing facilities, Daewoong Pharmaceutical provides a total healthcare solution to patients across the globe. Daewoong Pharmaceutic offers items in therapeutic areas, such as endocrinology, central nervous system, musculoskeletal, nephrology, antineoplastic, cardiovascular, and other diseases. More information about Daewoong Pharmaceutical can become found at https://www.daewoong.co.kr/ .
Regarding Sonoma Pharmaceutical drugs, Inc.
Sonoma Pharmaceuticals is a global health care leader for developing and producing stable hypochlorous acidity (HOCl) products for a broad range associated with applications, which includes wound treatment, animal health care, vision care, nasal care, oral care, disinfectant use plus dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid solution (HOCl) show it in order to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s sits firmly HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate pores and skin, and oxygenates the cells in the area treated, assisting the particular body in its natural recovery process. The company’s products are sold either directly or via partners in 55 countries worldwide plus the company actively seeks new distribution partners. The company’s principal office is within Boulder, Colorado, with production operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can end up being found in www.sonomapharma.com . For partnership opportunities, please contact [email protected] .
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions from the Private Securities Litigation Reform Act associated with 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Incorporation. and the subsidiaries (the “company”). These forward-looking statements are identified by the use of words like “continue, ” “develop” and “expand, ” among others. Forward-looking statements with this press release are subject to certain risks plus uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory medical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical outcomes may not be replicated in actual patient settings, protection offered by the carrier’s patents and patent applications may be challenged, invalidated or even circumvented by its competitors, the available market with regard to the industry’s products will not be as large as expected, the company’s items will never be able to penetrate one or more targeted markets, revenues will not really be sufficient to meet you can actually cash needs, fund further development, as well as uncertainties relative to the particular COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory plus marketing requirements in different countries and municipalities, plus other risks detailed from time to time in the company’s filings with the Investments and Exchange Commission. The particular company disclaims any obligation to update these forward-looking statements, except as needed by law.
Sonoma Pharmaceuticals™ and Microcyn ® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other art logos and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceutical drugs, Inc.
SOURCE: Sonoma Pharmaceuticals, Inc.